Amneal Pharmaceuticals, Inc. AMRX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $282.03M+155% | $110.55M+20.8% | $91.54M+252% | $25.98M-89.5% | ||
| $28.84M+267% | $7.87M+4.0% | $7.57M-18.2% | $9.25M+3.4% | ||
| $10.34M-63.9% | $28.61M+137% | -$77.23M-110% | $741.79M+12.0% | ||
| $606.3M-1.0% | $612.45M+5.3% | $581.38M+9.5% | $530.74M+8.4% | ||
| $98.4M+21.9% | $80.72M-2.4% | $82.69M-20.2% | $103.57M-6.0% | ||
| $1.91B+20.4% | $1.59B+15.2% | $1.38B-2.4% | $1.41B-7.1% | ||
| $442.95M+4.2% | $424.91M-5.1% | $447.57M-4.7% | $469.82M-8.6% | ||
| $595.47M-0.3% | $597.44M-0.2% | $598.63M0.0% | $598.85M+1.0% | ||
| $563.5M-23.1% | $732.38M-17.7% | $890.42M-18.8% | $1.1B-6.1% | ||
| $57.81M-3.9% | $60.13M+8.3% | $55.52M-46.2% | $103.22M+401% | ||
| $3.68B+5.1% | $3.5B+0.8% | $3.47B-8.6% | $3.8B-3.6% | ||
| $6.76M-97.0% | $224.21M+557% | $34.13M+13.9% | $29.96M-2.1% | ||
| $58.8M+25.0% | $47.04M-3.8% | $48.91M-17.4% | $59.23M-7.5% | ||
| $881.63M-22.0% | $1.13B+33.4% | $846.6M+12.5% | $752.8M+11.2% | ||
| $2.57B+18.7% | $2.16B-9.4% | $2.39B-7.9% | $2.59B-3.3% | ||
| $58.37M-2.9% | $60.1M-1.5% | $61.03M-5.0% | $64.26M+1.4% | ||
| —— | —— | —— | $87.47M+125% | ||
| $2.79B+15.5% | $2.42B-5.8% | $2.56B-9.6% | $2.84B-1.4% | ||
| $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | ||
| $571.79M+2.1% | $560.21M+3.9% | $539.24M-22.0% | $691.63M+5.1% | ||
| -$535.01M+11.9% | -$607.06M-23.8% | -$490.18M-20.7% | -$406.18M-47.1% | ||
| -$110.73M-69.0% | -$65.51M-103% | -$32.35M-425% | $9.94M+140% | ||
| -$535K-118% | -$245K-207% | $230K+100% | -$114.44M-1,825% | ||
| -$70.79M+35.2% | -$109.27M-652% | $19.78M-93.4% | $298.42M-17.2% | ||
| $3.68B+5.1% | $3.5B+0.8% | $3.47B-8.6% | $3.8B-3.6% | ||
| —— | —— | —— | —— | ||
| $57.81M-3.9% | $60.13M+8.3% | $55.52M-46.2% | $103.22M+401% | ||
| $563.5M-23.1% | $732.38M-17.7% | $890.42M-18.8% | $1.1B-6.1% | ||
| $57.81M-3.9% | $60.13M+8.3% | $55.52M-46.2% | $103.22M+401% | ||
| $57.81M-3.9% | $60.13M+8.3% | $55.52M-46.2% | $103.22M+401% | ||
| $71.82M-16.0% | $85.48M+26,950% | $316K-99.7% | $107.48M+85.3% | ||
| $43.26M+36.2% | $31.76M-58.8% | $76.99M-28.4% | $107.48M+85.3% | ||
| $2.69B+7.9% | $2.49B-1.5% | $2.53B-7.8% | $2.75B-3.3% | ||
| $0— | $0— | $0— | $0— | ||
| $71.82M-16.0% | $85.48M+26,950% | $316K— | —— | ||
| -$535K-118% | -$245K-207% | $230K+100% | -$114.44M-1,825% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amneal Pharmaceuticals, Inc.'s total assets?
- Amneal Pharmaceuticals, Inc. (AMRX) holds $3.5B in total assets, up 5.2% year over year.
- How much debt does Amneal Pharmaceuticals, Inc. have?
- Amneal Pharmaceuticals, Inc. carries $2.6B in total debt against -$45.4M of shareholders' equity, a debt-to-equity ratio of 127.90.
- How much cash does Amneal Pharmaceuticals, Inc. have?
- Amneal Pharmaceuticals, Inc. holds $197.7M in cash and equivalents.
- Can Amneal Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 2.47 — current assets exceed current liabilities.
- Where does Amneal Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
